All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
An Open-Label, Multicenter, Randomized Phase 3 Study of First-Line Encorafenib Plus Cetuximab with or without Chemotherapy Versus Standard of Care Therapy with a Safety Lead-In of Encorafenib and Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer
High Dose Re-Irradiation Utilizing Advanced Defromable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression on or after Standard First-Line Therapy
A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.